AIM — AIM ImmunoTech Inc.

—
NYSE · Health Care · Biotechnology · CIK 946644 ·
Last close
$0.14
Market Cap
$5.43M
52W High
$1.82
52W Low
$0.12
ADV30
533,858
Next earnings
—
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — — — —
Mar 2026 22,000 18,000 -2,226,000 -3,023,000 8,585,000 5,816,000 6,460,000
Dec 2025 21,000 -19,000 -2,952,000 -4,175,000 5,782,000 2,985,000 15,565,000
Sep 2025 26,000 -42,000 -2,447,000 -3,284,000 5,494,000 2,347,000 11,571,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-11,315,000
Investing CF
$918,000
Financing CF
$15,315,000
CapEx
$-413,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.36
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-443,809,000
Inventory
—
Receivables
$0
ST Investments
$63,000
EBIT TTM
$-12,284,000
Pretax Income TTM
$-13,276,000
Interest Exp TTM
$992,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$95,000
EBITDA
$-10,734,000
Free Cash Flow
$-14,060,500
Enterprise Value
$-1,519,298
Total Cash
$9,964,000
Total Debt
$3,921,000
Shares Out
39,919,844
Trailing EPS
$-2.98
Book Value
$-3.19
ROE
-2382.3%
ROA
-82.6%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 88,000 -11,664,000 -13,958,000 5,782,000 15,565,000 -9,783,000 -10,957,000
Dec 2024 170,000 -19,772,000 -17,320,000 8,608,000 9,930,000 -1,322,000 -14,888,000
Dec 2023 202,000 -31,916,000 -28,962,000 19,381,000 9,147,000 10,234,000 -21,267,000
Dec 2022 141,000 -19,923,000 -19,445,000 40,488,000 2,020,000 38,468,000 -16,108,000

TTM Snapshot

Revenues TTM
$95,000
NetIncome TTM
$-14,270,000
OpCashFlow TTM
—
Assets (Latest)
$12,731,000
Forward EPS
$-0.37

Peers — same industry

TickerNameMarket CapLastDaily %
ZEOX Zeo ScientifiX, Inc. $6.27M $0.80 —
SCLX Scilex Holding Co $4.52M $0.64 —
ALGS Aligos Therapeutics, Inc. $7.40M $1.36 —
CUBT Curative Biotechnology Inc $7.56M $0.85 —
LIMN Liminatus Pharma, Inc. $3.77M $2.81 —

News headlines (Yahoo Finance, 1h cache)

AIM ImmunoTech Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
2026-11-18 13:30 · Yahoo
AIM ImmunoTech Approaches Major Clinical Inflection Point with Phase 2 Pancreatic Cancer Data Expected Q1 2027; Reports Third Quarter 2026 Financial Results
2026-11-13 13:30 · Yahoo
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
2026-11-10 14:20 · Yahoo
AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer
2026-11-05 14:13 · Yahoo
AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
2026-10-07 13:14 · Yahoo
AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential
2026-10-05 13:22 · Yahoo
AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
2026-09-30 12:44 · Yahoo
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
2026-09-22 12:55 · Yahoo
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
2026-09-09 13:03 · Yahoo
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
2026-08-27 13:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.